Current Report · Items 8.01, 9.01 · 8-K

Valion Bio, Inc.

VBIONASDAQEQUITYCurrent

Other Events

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Description Number ───────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release, dated September 30, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

Filed Oct 1, 2026Accepted Oct 1, 2026, 7:45 AM EDTCIK 1787740Accession 0001683168-26-007514

View company →Permanent SEC source ↗

Press release in this filing

Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity →

Company context

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. An emerging growth company may take advantage of specified reduced reporting requirements that are otherwise generally applicable to public companies. As a result:

Current securities

VBIONASDAQ · EQUITY · Current

Historical securities (1)

TIVCNASDAQ · EQUITY · Historical · closed Apr 27, 2026

Recent company filings

Registered securities in this filing

Valion Bio, Inc. · 8-K · Filed 2026-10-01

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol: VBIO
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-09-30

Dimensions: Not supplied

Accession 000168316826007514 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 9.01Item 9.01 - Financial Statements and Exhibits

Get the free weekly BCS email.